SelectQuote: Efficiency Is The Name Of The Game, A Strong FY26 Ahead

Amidst broader market rotation from crowded large-cap trades, SelectQuote (SLQT) is highlighted as a modestly valued opportunity with significant upside potential. The company projects robust FY26 growth, targeting 11% revenue and 7% adjusted EBITDA increases, supported by stabilizing recurring revenue from its SelectRx division and a long-term goal of 20% adjusted EBITDA margins. Anticipated increases in Medicare Advantage reimbursement rates for 2026 are expected to further boost carrier profitability and SelectQuote's revenue, leading an analyst with a beneficial long position to reiterate a Buy rating on SLQT.

Analysis

The current market environment suggests a potential rotation from crowded, high-valuation large-cap stocks like Palantir (PLTR) towards opportunities offering growth at a reasonable price, with SelectQuote (SLQT) identified as a prime candidate. The company's fundamental outlook is presented as bullish, underpinned by specific fiscal year 2026 guidance forecasting 11% revenue growth and 7% adjusted EBITDA growth. This growth is supported by operational stabilization through its SelectRx division, which provides a source of recurring revenue, and a long-term management goal of achieving 20% adjusted EBITDA margins. A significant external catalyst is the expected increase in Medicare Advantage reimbursement rates in 2026, which is projected to boost carrier profitability and directly benefit SelectQuote's revenue stream. Despite these positive indicators and a strong forward-looking outlook, the article asserts that the stock remains modestly valued, presenting a potential upside opportunity.

Key Decisions for Investors

• Investors seeking growth-at-a-reasonable-price (GARP) exposure within the healthcare sector may find SLQT compelling due to its strong FY26 guidance and a clear catalyst from upcoming Medicare Advantage rate changes.
• It is crucial to monitor the performance of the SelectRx division for continued business stabilization and track the company's progress toward its long-term 20% adjusted EBITDA margin target as key performance indicators.
• Be mindful that the investment thesis relies on forward-looking guidance and an anticipated regulatory rate increase in 2026, which carry execution and timing risks, and note the author's disclosed long position.